VOR
Vor Biopharma Inc. · Healthcare
16.85
3.56%(+0.58)
Close19.00
12.76%(+2.15)
After HoursLast Updated: — ET
52W L: $2.6252W H: $65.80
$17.29
CHG+2.51 (+16.98%)
H$19.70
L$11.70
VOL15M
VOR (1h)
Vor Biopharma Inc. · Healthcare
Stock News Markets edge higher before Iran deadline: Global equities were mixed and oil volatile ahead of President Trump's deadline on Iran's Hormuz reopening,
Shares of Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) have earned a consensus rating of "Moderate Buy" from the thirteen ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, six have given a buy rating and
Vor Biopharma (VOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The average of price targets set by Wall Street analysts indicates a potential upside of 107.8% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on April 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 42,650 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 9,050 shares of Vor Bio's common stock to 9 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren's disease
RA CAPITAL MANAGEMENT, L.P.
director, 10 percent owner:
258,475 SH @ $18.23
2026-04-02
RA CAPITAL MANAGEMENT, L.P.
director, 10 percent owner:
1,525 SH @ $19.06
2026-04-02
RA CAPITAL MANAGEMENT, L.P.
director, 10 percent owner:
537,754 SH @ $16.51
2026-04-06
RA CAPITAL MANAGEMENT, L.P.
director, 10 percent owner:
44,728 SH @ $17.31
2026-04-06
RA CAPITAL MANAGEMENT, L.P.
director, 10 percent owner:
6,775 SH @ $18.50
2026-04-06
TCG Crossover GP II, LLC
10 percent owner
0 SH @ $0.00
2026-03-30
RA CAPITAL MANAGEMENT, L.P.
director, 10 percent owner:
4,625,346 SH @ $10.81
2025-12-18
RA CAPITAL MANAGEMENT, L.P.
director, 10 percent owner:
3,000 SH @ $12.80
2025-12-18